KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 12.83%.

  • Acadia Pharmaceuticals' EBITDA Margin rose 2000.0% to 12.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.01%, marking a year-over-year increase of 109300.0%. This contributed to the annual value of 24.1% for FY2024, which is 342000.0% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' EBITDA Margin stood at 12.83%, which was up 2000.0% from 12.24% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' EBITDA Margin peaked at 59.13% during Q4 2024, and registered a low of 97.88% during Q1 2022.
  • Its 5-year average for EBITDA Margin is 13.55%, with a median of 11.63% in 2021.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 596100bps in 2021, then tumbled by -352100bps in 2022.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' EBITDA Margin stood at 34.15% in 2021, then rose by 1bps to 33.75% in 2022, then skyrocketed by 145bps to 15.12% in 2023, then skyrocketed by 291bps to 59.13% in 2024, then crashed by -78bps to 12.83% in 2025.
  • Its EBITDA Margin stands at 12.83% for Q3 2025, versus 12.24% for Q2 2025 and 7.9% for Q1 2025.